Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InVivo names new CEO

This article was originally published in Clinica

Executive Summary

Cambridge, Massachusetts-based InVivo Therapeutics has named Mark Perrin chief executive officer – effective 6 January 2014. Upon his appointment, Mr Perrin will also become a member of the company's board of directors. Prior to joining the company – which specializes in drug delivery technologies for spinal cord injuries – Mr Perrin was president of Dennan Consulting, a biotech consulting firm. Mr Perrin replaces interim CEO Michael Astrue, who has been filling in since previous leader Francis Reynold stepped down in August due to a medical condition. Meanwhile, InVivo has also promoted Lisa Crockett to vice-president, regulatory and Kristin Neff to vice-president, clinical operations, effective 1 January 2014. The firm also recently made Steven McAllister interim CEO, making him the third person to head up its finance division in the last three months. InVivo saw its share price plunge in August after delaying its first-in-human trials of its biopolymer scaffold.

You may also be interested in...



A Backstage View Of Roche’s Recent Collaborations

In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.

Fact File: Coronavirus Medtech And Diagnostic Updates

As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.

Making Progress Against Rare Diseases

Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.

Topics

UsernamePublicRestriction

Register

MT101209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel